Year-end report 2010 · Net sales for the year were SEK 80.5 million (83.2). Currency effects had a negative impact on sales of SEK 8 million for the year. · Net sales for the fourth quarter were SEK 20.0 million (19.1). Currency effects had a negative impact on sales of SEK 1 million for the quarter. · The underlying sales growth of Olerup SSP products for the fourth quarter was very strong. Growth for Olerup GmbH in local currency was 11 % and for Olerup Inc. was a notable 36 %. · Operating loss (EBIT) for the year was SEK 8.1 million (+18.7), with a loss of SEK 4.0 million (+0.5) in the fourth quarter. Nonrecurring costs had a negative impact on fourth quarter results of SEK 3.3 million. In the comparative figures for 2009, Absorber is only included from November 18 and Olerup Inc. not at all. · Loss after tax for the year was SEK 13.6 million (+10.2). · Loss per share basic and diluted was SEK 0.58 (+0.69) for the year. · Equity per share was SEK 33.43 (34.71). Key events in the fourth quarter · LinkMed streamlined its organization in conjunction with new strategic direction. · LinkMed appointed Ondra Partners as financial advisors in conjunction with the ongoing exit processes. · The patient logistics solution PatLog® from ONCOlog Medical is included in the proton therapy facility that the Belgian company IBA has been commissioned to deliver to a new center in Dimitrovgrad, Russia. · ONCOlog Medical's PatLog® system was installed at a radiotherapy center in Germany. · Likvor received an order for the Likvor CELDA® system from the Örebro University Hospital. Key events after the period end · Distribution agreements for the Brazilian market were entered into by the transplantation companies · Likvor's CELDA® system was purchased by the Kuopio University Hospital in Finland. · Olerup SSP increased its product range through two exclusive sales agreements. Comments from CEO Ingemar Lagerlöf on the quarter: “Our intensive marketing and sales efforts have started to generate strong results. The build-up of our operations in the U.S. involved costs of SEK 12 million for the year. It is therefore with great pleasure that I am able to announce a strong sales growth of 36 percent in the U.S. for the fourth quarter. Our European team also generated a solid 11 percent growth. Over the past two quarters we incurred higher one-off costs, amounting to SEK 9.9 million, in order to transform LinkMed from a broad life science investment company to a global operator in the transplantation sector. In 2011, we will work intensively to generate high growth, mainly organic; however, we may also expand our product range through acquisitions and licensing.” For more information please contact: Ingemar Lagerlöf, CEO, Cell +46 (0)70-873 2733 or email ingemar.lagerlof@LinkMed.se Okee Williams, Portfolio Manager, Cell +46 (0)70- 600 5364 or email okee.williams@LinkMed.se The information in this interim report is such that LinkMed AB (publ) is required to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. This information was released for publication on February, 25 2011 at 08:00 CET. This report and earlier financial reports are available at www.linkmed.se
Year-end report 2010
| Source: Allenex AB
Attachments
